Advertisement
Advertisement


News

Kidney and Bone Markers Improve in Patients With Renal Impairment After Switch from TDF to TAF

August 26, 2016

Proteinuria, albuminuria and bone mineral density (BMD) improved significantly in HIV-positive people with mild or moderate renal impairment who switched to once-daily coformulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide (E/C/F/TAF, Genvoya) for 48 weeks. Creatinine clearance did not change significantly after the switch in this single-arm open-label study.

TAF is licensed as part of three fixed-dose coformulations: E/C/F/TAF (Genvoya), rilpivirine/F/TAF (Odefsey) and F/TAF (Descovy). Compared with tenofovir disoproxil fumarate (TDF, Viread), TAF delivers less tenofovir to plasma and more to target cells and so should have a better toxicity profile. TDF is well known for its impact on kidney function and BMD. E/C/F/TAF proved virologically noninferior to E/C/F/TDF in two randomized phase 3 trials and had less renal and bone toxicity indicated by standard markers.

In the new study, an international team recruited adults with a viral load below 50 copies/mL for at least six months, a CD4 count at or above 50 cells/mm3 and mild to moderately impaired renal function, defined as an estimated glomerular filtration rate (eGFR) between 30 and 69 mL/min. The study excluded patients with a new AIDS illness within 30 days of screening and patients positive for hepatitis B surface antigen or hepatitis C antibody. All participants switched from their ongoing antiretroviral regimen to once-daily coformulated E/C/F/TAF.

Advertisement
The 242 study participants had a median age of 58 years (range 24 to 82) and a median CD4 count of 632 cells/mm3; 21% were women; and 18% were black. Median eGFR by the Cockroft-Gault formula stood at 56 mL/min; 42% of participants had significant proteinuria (urine protein to creatinine ratio >200 mg/g); and 49% had significant albuminuria (urine albumin to creatinine ratio ≥30 mg/g). Two-thirds of study participants (65%) switched from a TDF-containing combination.

Through 48 weeks, creatinine clearance did not change significantly regardless of whether baseline eGFR lay above or below 50 mL/min or whether the previous regimen included TDF. In a 32-patient substudy, iohexol-determined actual GFR did not change through 24 weeks of E/C/F/TAF therapy. Albuminuria, total proteinuria and tubular proteinuria all improved significantly through 48 weeks in patients switching from a TDF regimen; these measures of renal function did not change significantly in patients switching from a non-TDF regimen. Overall prevalence of significant proteinuria decreased from 42% to 11%, while prevalence of significant albuminuria fell from 49% to 21%.

Hip and spine BMD increased by an average 1.47% and 2.29%, respectively, through 48 weeks after the switch to E/C/F/TAF. BMD improved significantly only in patients switching from a TDF regimen while remaining stable in those switching from non-TDF regimens. Total to high-density lipoprotein cholesterol ratio did not change significantly with E/C/F/TAF in patients initially taking a TDF regimen or a non-TDF regimen.

Eight patients (3%) discontinued the study drug because of adverse events, including two because of a decreased glomerular filtration rate determined by the Cockroft-Gault formula. No study participants had laboratory evidence of proximal renal tubulopathy or Fanconi syndrome.

Through 48 weeks, 222 study participants (92%) maintained a viral load below 50 copies/mL, and three patients had virologic failure. Pharmacokinetic analysis in 30 patients determined that elvitegravir and cobicistat concentrations were equivalent to those in HIV-positive people taking E/C/F/TAF without renal impairment, regardless of whether eGFR lay above or below 50 mL/min. Emtricitabine concentrations were higher in study participants than in HIV-positive patients taking E/C/F/TAF without renal impairment because emtricitabine is primarily cleared by the kidneys.

The researchers propose that the renal and bone improvements seen in patients who switched from a TDF regimen "likely represent a reduction in the off-target renal and bone effects of plasma [tenofovir] concentrations, which are 90% lower with TAF." They stress that participants with eGFR below 50 mL/min, who currently need TDF and FTC dose adjustments, had stable eGFR and significantly improved tubular function through 48 weeks taking E/C/F/TAF without dose adjustment.

Mark Mascolini writes about HIV infection.


Copyright © 2016 Remedy Health Media, LLC. All rights reserved.


Related Stories

Tenofovir Levels in Blood 4-Fold Higher With TAF Than TDF
Switching to Emtricitabine/Tenofovir Alafenamide (F/TAF) Maintains Viral Suppression With Better Bone and Kidney Safety
Does Tenofovir (TDF) Cause Liver Injury?



This article was provided by TheBodyPRO.com.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.